Description
Adjunctive therapies are not only vital to the success of cancer treatments, enhancing compliance and outcomes, but they are also a dynamic area of research and development in a variety of disciplines from drug delivery to biologics. It also happens to be the largest portion of the overall cancer therapeutics market.
This report provides the reader with a comprehensive analysis of the worldwide market for therapeutics to treat and manage symptoms in cancer patients. Market information, including market size and growth, is provided for 2003 to 2010 on various product subcategories included in the major segments:
- antinauseants and antiemetics
- pain management
- blood modifiers
- infection control
- other therapies.
In addition, competitive market share and a four-region geographic breakdown are provided for the base year 2005. The study also covers issues and trends affecting the market, research and development pipelines, demographics, cancer statistics, the epidemiology of side effects, and more.
Table of Contents
Chapter one: Executive Summary
- Introduction
- Scope and Methodology
- Size and Growth of the Market
- Issues and Trends Affecting the Global Market
- Leading Competitors
Chapter Two: Introduction
- Overview of Cancer
- Biology of Cancer
- Treatments and Symptoms
- Chemotherapy
- Radiation Therapy
Adjunctive Therapy Overview: Product Types and Administration
- Oral
- Rectal
- Transdermal and Nasal
- Intravenous or Subcutaneous
Demographics, Prevalence, Incidence, Mortality
Chapter three: Issues and Trends
- Overview
- Geographical Trends
- United States
- European Union
- Japan
- Regulatory Authorities
- Clinical Trials
- New Indications
- Lifestyle and Social Issues
- Barriers to Adjunctive Therapies
- Drug Delivery Advancements
- Pain Management Measures
- Oxycontin Issues
- Cancer-Related Fatigue Issues
- Individualized Chemotherapy
- Chemotherapy and Memory Loss
chapter Four: Antinauseants and Antiemetics
- Overview
- Products
- Serotonin Receptor Antagonists
- Phenothiazines
- Metoclopramide and Other Drugs
- Drug Delivery Methods for Antinauseants and Antiemetics
- Research and Development
- Market Overview
- Competitive Analysis
chapter Five: Pain Management
- Overview
- Pain Pathways
- Primary Cancer Pain
- Breakthrough Cancer Pain
- Cancer Pain Delivery Methods
- Oral
- Oral Transmucosal
- Parenteral
- Transdermal
- Rectal
- Intranasal
- Description of Products
- Primary Cancer Pain Medications
- Non-Narcotic Analgesics
- Narcotic Analgesics
- Breakthrough Cancer Pain Medications
- Antidepressants
- Anticonvulsants
- Corticosteroids
- Bisphosphonates and Calcitonins
- Radiopharmaceuticals
- Other
- Research and Development
- Market Overview
- Competitive Analysis
chapter six: Biological Response Modifiers
- Overview
- Description of Products
- Hematopoietic Growth Factors
- Granulocyte Colony-Stimulating Factor (G-CSF)
- Granulocyte-Macrophage Colony-stimulating Factor (GM-CSF)
- Epoetin Alpha
- Darbepoetin Alfa
- Epoetin Beta
- Human keratinocyte growth factor
- Cytomodulatory Agents
- Research and Development
- Market Overview
- Competitive Analysis
chapter seven: Infection Control
- Overview
- Description of Products
- Anti-Bacterials and Antivirals
- Antifungals
- Research and Development
- Market Overview
- Competitive Analysis
chapter eight: Other Adjunctive Therapies
- Overview
- Fatigue
- Anorexia/Cachexia/Weight Loss
- Diarrhea
- Constipation
- Alopecia (Hair Loss)
- Radiation-Induced Dermatitis
- Other
Description of Products
- Fatigue
- Anorexia/Cachexia/Weight Loss
- Diarrhea
- Constipation
- Hair Loss
- Radiation-Induced Dermatitis
- Research and Development
- Market Overview
- Competitive Analysis
Chapter Nine: Market Summary
- Overview
- Market Size
- Competitive Analysis
- Market Analysis
chapter Ten: Company Profiles
- Introduction
- Competitive Summary
- Abbott Laboratories
- Amgen, Inc.
- Bayer Corp.
- Cephalon , Inc
- Chugai Pharmaceutical Company Ltd.
- Eli Lilly & Co.
- GlaxoSmithKline plc
- Johnson & Johnson
- Novartis Pharmaceuticals Corp.
- Pfizer, Inc.
- Roche Group
- Sanofi -Aventis
APPENDIX: Company Directory
List of Exhibits
Chapter one: Executive Summary
- Table 1-1: Cancer Incidence and Deaths as a Percentage to Population by Selected Country/Region 2005
- Table 1-2: Summary Table: The World Market for Adjunctive Therapies in Cancer Revenues and Growth Rate 2003-2010 Figure 1-1: Summary Figure: The World Market for Adjunctive Therapies in Cancer 2003-2010
Chapter Two: Introduction
- Table 2-1: List of Cancers
- Table 2-2: Side Effects Associated with Chemotherapy Table 2-3: Side Effects Associated with Radiation Therapy Table 2-4: Population by Country 2003-2010 Figure 2-1: Population by Major Market Country 2005 vs. 2010 Table 2-6: Cancer Incidence and Mortality by Major Market Country 2005 Figure 2-3: Cancer Incidence by Major Market Country 2005 Figure 2-4: Cancer Deaths by Major Market Country 2005 Table 2-8: Cancer Incidence and Deaths as a Percentage to Population by Selected Major Market Country/Region
chapter Four: Antinauseants and Antiemetics
- Figure 4-1: Incidence of Emesis in Cancer Patients
- Table 4-1: Chemotherapy Agents and Level of Emetic Potential
- Table 4-2: Time Course of Selected Products in Nausea and Vomiting
- Table 4-3: Selected Prescription Antinauseants/Antiemetics by Available Delivery Method
- Table 4-4: Antinauseants and Antiemetics in Development for Treatment of Cancer related Nausea and Vomiting
- Table 4-5: The Adjunctive Antinauseant and Antiemetic Market 2003-2010
- Figure 4-1: The Adjunctive Antinauseant and Antiemetic Market 2003-2010
- Table 4-6: The Adjunctive Antinauseant and Antiemetic Market, Estimated Sales by Geographic Region, 2005
- Figure 4-2: The Adjunctive Antinauseant and Antiemetic Market by Geographic Region, 2005
- Table 4-7: Leading Suppliers’ Revenues and Share of the Antinauseants and Antiemetics Segment 2005
- Figure 4-3: Leading Suppliers’ Shares of the Antinauseants and Antiemetics Segment 2005
chapter Five: Pain Management
- Figure 5-1: Incidence of Pain in Cancer Patients
- Table 5-1: The World Health Organization Three-Step Analgesic Ladder
- Table 5-2: Selected Prescription Non-Narcotic Analgesics by Available Delivery Method
- Table 5-3: Selected Over-the-Counter Non-Narcotic Analgesics by Available Delivery Method
- Table 5-4: Selected Prescription Narcotic Analgesics by Available Delivery Method
- Table 5-5: Selected Prescription Antidepressants Used for Cancer Pain by Available Delivery Method
- Table 5-6: Selected Prescription Anticonvulsants Used for Cancer Pain by Available Delivery Method
- Table 5-7: Selected Prescription Corticosteroids Used for Cancer Pain by Available Delivery Method
- Table 5-8: Selected Prescription Bisphosphonates and Calcitonins Used for Cancer Pain by Available Delivery Method
- Table 5-9: Selected Prescription Radiopharmacuticals Used for Cancer Pain by Available Delivery Method
- Table 5-10: Pain Management Products in Development for Treatment of Cancer Related Pain
- Table 5-3: The Adjunctive Pain Management Market 2003-2010
- Figure 5-1: The Adjunctive Pain Management Market 2003-2010
- Table 5-4: The Adjunctive Pain Management Market, Estimated Sales by Geographic Region, 2005
- Figure 5-2: The Adjunctive Pain Management Market by Geographic Region, 2005
- Table 5-5: Leading Suppliers’ Revenues and Shares of the Cancer Pain Management Segment 2005
- Figure 5-3: Leading Suppliers’ Shares of the Cancer Pain Management Segment 2005
chapter six: Biological Response Modifiers
- Figure 6-1: Frequency of Bone Marrow Suppression in Cancer Patients
- Table 6-1: Selected Biological Response Modifiers and Available Delivery Method
- Table 6-2: Biological Response Modifiers in Development for Treatment of Cancer Related Infection
- Table 6-3: The Adjunctive Biological Response Modifier Market 2003-2010
- Figure 6-2: The Adjunctive Biological Response Modifier Market 2003-2010
- Table 6-4: The Adjunctive Biological Response Modifier Market, Estimated Sales by Geographic Region, 2005
- Figure 6-3: The Adjunctive Biological Response Modifier Market, Market by Geographic Region, 2005
- Table 6-5: Leading Suppliers’ Revenues and Shares of the Biological Response Modifiers Segment 2005
- Figure 6-4: Leading Suppliers’ Market Share of the Biological Response Modifiers Segment 2005
chapter seven: Infection Control
- Table 7-1: Common Infection Sites and Organisms
- Figure 7-1: Frequency of Infection in Cancer Patients
- Table 7-2: Selected Prescription Antibacterial and Antiviral Agents and Available Delivery Method
- Table 7-3: Selected Prescription Antifungals and Available Delivery Method
- Table 7-4: Anti-Infective Agents and Antifungals in Development for Treatment of Cancer related Infection
- Table 7-3: The Adjunctive Infection Control Market 2003-2010 Figure 7-1: The Adjunctive Infection Control Market 2003-2010
- Table 7-4: The Adjunctive Infection Control Market Estimated Sales by Geographic Region, 2005
- Figure 7-2: The Adjunctive Infection Control Market by Geographic Region, 2005
- Table 7-5: Leading Suppliers’ Revenues and Shares of the Infection Control Segment 2005
- Figure 7-3: Leading Suppliers’ Market Shares of the Infection Control Segment 2005
chapter eight: Other Adjunctive Therapies
- Figure 8-1: Frequency of Fatigue in Cancer Patients
- Figure 8-2: Incidence of Anorexia/ Cachexia/Weight Loss in Cancer Patients
- Figure 8-3: Incidence of Diarrhea in Cancer Patients
- Figure 8-4: Incidence of Constipation in Cancer Patients
- Table 8-1: Selected Chemotherapy Agents and Level of Hair Loss Potential
- Figure 8-5: Frequency of Hair Loss in Cancer Patients
- Figure 8-6: Prevalence of Other Conditions in Cancer Patients (Sexual/ Reproductive, Heart, Liver, Lung, Nerve, Kidney/Urinary Damage)
- Table 8-2: Selected Prescription and Non-prescription Products to Minimize Symptoms of Fatigue in Cancer Patients and Their Available Delivery Method
- Table 8-3: Selected Prescription Products for the Treatment of Anorexia/ Cachexia in Cancer Patients and Available Delivery Method
- Table 8-4: Selected Prescription and Non-prescription Products for the Treatment of Diarrhea in Cancer Patients and Available Delivery Method
- Table 8-5: Selected Prescription and Non-prescription Products for the Treatment of Constipation in Cancer Patients and Available Delivery Method
- Table 8-6: Selected Prescription and Non-prescription Products for the Treatment of Radiation-induced Dermatitis
- Table 8-7: Other Adjunctive Therapies in Development for Treatment of Cancer
- Table 8-8: The Adjunctive Therapy Other Products Market 2003-2010
- Figure 8-7: The Adjunctive Therapy Other Products Market 2003-2010
- Table 8-9: The Adjunctive Therapy Other Products Market, Estimated Sales by Geographic Region, 2005
- Figure 8-8: The Adjunctive Therapy Other Products Market by Geographic
- Region, 2005
Chapter Nine: Market Summary
- Table 9-1: The World Market for Adjunctive Therapies in Cancer 2003-2010
- Figure 9-1: The World Market for Adjunctive Therapies in Cancer 2003-2010
- Table 9-2: The Global Market for Adjunctive Therapies in Cancer by Type, 2003-2010
- Figure 9-2: The World Market for Adjunctive Therapies in Cancer Revenues by Type 2003-2010
- Figure 9-3: The World Market for Adjunctive Therapies in Cancer Estimated Market Share by Product Type 2005
- Table 9-5: Leading Suppliers, Products, and Segments of Participation 2005
